Zynerba Pharma (ZYNE) – Company Press Releases
-
HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE
-
Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions
-
Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023
-
Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023
-
HARMONY BIOSCIENCES ANNOUNCES EXTENSION OF TENDER OFFER TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.
-
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposi
-
Moore Kuehn Encourages SOVO, DBTX, DM and ZYNE Investors to Contact Law Firm
-
Moore Kuehn Encourages CTG, KLR, ZYNE, and DBTX Investors to Contact Law Firm
-
Moore Kuehn Encourages ZYNE, ESTE, SOLO, and CEQP Investors to Contact Law Firm
-
HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.
-
Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting
-
Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting
-
Zynerba Pharmaceuticals Announces Further Adjournment of Annual Meeting
-
Zynerba Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
-
Zynerba Pharmaceuticals Announces Partial Adjournment of Annual Meeting
-
Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
-
Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights
-
Zynerba Pharmaceuticals Presents Data on Zygel™ at the 55th Gatlinburg Conference
-
Zynerba Pharmaceuticals Presents Data on Zygel™ at the 55th Gatlinburg Conference
-
Zynerba Pharmaceuticals Announces Poster Presentations at the 55th Gatlinburg Conference
-
Zynerba Pharmaceuticals Announces Poster Presentations at the 55th Gatlinburg Conference
-
Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
-
Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
-
Zynerba Pharmaceuticals Confirms Not Holding Cash Deposits or Securities at Silicon Valley Bank
-
Zynerba Pharmaceuticals Confirms Not Holding Cash Deposits or Securities at Silicon Valley Bank
-
Zynerba Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
-
Zynerba Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
-
Zynerba Pharmaceuticals to Present at the Cowen 43rd Annual Health Care Conference
-
Zynerba Pharmaceuticals to Present at the Cowen 43rd Annual Health Care Conference
-
Zynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X Syndrome
-
Zynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X Syndrome
-
Zynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome
-
Zynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome
-
Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the Annual Meeting of the American College of Neuropsychopharmacology
-
Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the Annual Meeting of the American College of Neuropsychopharmacology
-
Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of Neuropsychopharmacology
-
Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of Neuropsychopharmacology
-
Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel™ in the Journal of Neurodevelopmental Disorders
-
Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel™ in the Journal of Neurodevelopmental Disorders
-
Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in 22q11.2 Deletion Syndrome
-
Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in 22q11.2 Deletion Syndrome
-
Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights
-
Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights
-
Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22q11.2 Deletion Syndrome
-
Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22q11.2 Deletion Syndrome
-
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthr
-
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthr
-
Zynerba Pharmaceuticals Announces Poster Presentation at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit
-
Zynerba Pharmaceuticals Announces Poster Presentation at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit
-
Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™
Back to ZYNE Stock Lookup
